Resmed (RMD) Raw Materials (2010 - 2026)

Resmed has reported Raw Materials for 17 years, with the latest figure at $350.9 million in Q1 2026.

• For the quarter ending Q1 2026, Raw Materials rose 2.31% year-over-year to $350.9 million; the trailing twelve-month figure through Mar 2026 stood at $350.9 million (up 2.31% YoY), and the FY2025 full-year result was $367.3 million, up 3.29% from the prior year.
• Raw Materials for Q1 2026 stood at $350.9 million, down from $374.7 million in the prior quarter.
• The five-year high for Raw Materials was $468.8 million in Q1 2023, with the low at $340.3 million in Q1 2022.
• Historically, Raw Materials has averaged $392.9 million across 5 years, with a median of $373.3 million in 2024.
• Annual changes were most pronounced in 2022 — Raw Materials soared 134.0% — and 2024, when it retreated 22.56%.
• Resmed's Raw Materials stood at $463.4 million in 2022, then gained by 0.82% to $467.2 million in 2023, then retreated by 21.92% to $364.8 million in 2024, then gained by 2.72% to $374.7 million in 2025, then declined by 6.36% to $350.9 million in 2026.
• The last three Raw Materials figures came in at $350.9 million (Q1 2026), $374.7 million (Q4 2025), and $363.4 million (Q3 2025), per Business Quant data.